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CASE REPORT
Left hepatectomy for cholangiocarcinoma: case report and
literature review
Hepatectomia a esquerda por colangiocarcinoma: relato de caso e revisão de literatura*
Antonio Luis de Vasconcelos Macedo1, Jaques Pinus2, João Guidugli Neto3, Vladimir Schraibman4
ABSTRACT
Cholangiocarcinoma is a rare biliary tract malignant tumor that
remains a major challenge for surgeons. It is associated with poor
prognosis and high morbidity and mortality rates even after surgical
treatment. Diagnosis by non-invasive methods (3D CT, MR
cholangiography) enables precise tumor staging in addition to
correctly selecting patients for surgery. The general consensus has
shown that surgery by completely resecting the tumor and leaving
free surgical margins is the treatment that offers the best prognosis
and the only chance of cure. Chemotherapy and radiotherapy in the
postoperative period do not seem to change survival or recurrence
rates, even in cases in which complete resection is performed.
Despite all diagnostic and therapeutic advances, the 5-year survival
rate remains 7-33%. Up to now, surgery is the treatment that offers
the best chances of cure. In the present study, we describe the
surgical treatment of a patient with cholangiocarcinoma with a
satisfactory outcome and present a review of the current treatment
in international literature for patients with cholangiocarcinoma.
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RESUMO
O colangiocarcinoma é um raro tipo de neoplasia maligna de vias
biliares que ainda permanece como um grande desafio aos cirurgiões.
Está associado a mau prognóstico e a altos níveis de morbimor-
talidade, mesmo após o tratamento cirúrgico. O diagnóstico por
métodos não-invasivos (TC 3D, colangio RNM) permite um
estadiamento acurado do tumor, além da seleção correta de
pacientes com indicação cirúrgica. O consenso geral mostra que o
tratamento cirúrgico através da completa ressecção tumoral com
margens livres cirúrgicas é o que oferece o melhor prognóstico e a
única chance de cura. O uso de agentes quimioterápicos e
radioterápicos no pós-operatório parece não alterar a sobrevida nem
o índice de recorrência, mesmo em casos de ressecção completa.
Apesar de todos os avanços diagnósticos e terapêuticos, a sobrevida
em 5 anos ainda se encontra entre 7 e 33%. Até o momento, o
tratamento cirúrgico é o que oferece as melhores chances de cura.
Neste trabalho relatamos o tratamento cirúrgico de um paciente
com diagnóstico de colangiocarcinoma que obteve boa evolução e
revisamos o tratamento atual da literatura mundial em pacientes
portadores de colangiocarcinoma.
Descritores: Colangiocarcinoma/cirurgia; Hepatectomia; Trato biliar/
patologia; Procedimentos cirúrgicos do trato biliar; Quimioterapia
INTRODUCTION
Cholangiocarcinoma is a rare biliary tract malignant tumor that
remains a major challenge for surgeons. It is associated with poor
prognosis and high morbidity and mortality rates even after surgical
treatment. Little is known about its etiology and pathogenesis(1).
It classically occurs in individuals aged over 60 years and is more
frequent in males, in a ratio of 3:2.
Clinically, patients present progressive jaundice associated with
abdominal pain and weight loss, and the physical examination is
generally inconclusive. The diagnosis is made through imaging
examinations, such as ultrasound, computerized tomography (CT)
and magnetic resonance cholangiography (MRC). The only
curative treatment is surgery, by resection of the biliary tract
associated with an occasionally extensive hepatectomy, and
cholangio-enteric bypass. In cases in which surgical resection is
contraindicated, palliative measures, such as endoscopic stenting
in the biliary tract or percutaneous transhepatic biliary drainage,
are carried out in order to improve jaundice and/or cholangitis
and extend survival.
Despite all diagnostic and therapeutic advances, the 5-year
survival rate remains 7-33%. So far, surgery is the treatment that
provides the best chances of cure(2-4).
CASE REPORT
We treated a Caucasian, 74 year-old patient, with a history of
intense epigastric pain associated with fever and chills for a
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week. On the initial physical examination, the patient had fever,
pain at palpation during deep breath (Murphy sign) and was
clinically anicteric. These findings let to a presumptive diagnosis
of cholangitis and laboratory tests and imaging examinations
were requested. The tests confirmed the diagnosis of cholangitis
and aroused the suspicion of biliary tract neoplasm. The MRC
showed an intraductal growing nodular lesion at the intrahepatic
bile duct projection of the IV-A segment, associated with
intrahepatic biliary tract dilation, retraction and edema of this
segment, leading to the diagnosis of an expanding lesion of
peripheral intraductal origin. Initially, cholangitis was treated
followed by surgery to resect the expanding lesion. The surgical
treatment consisted of expanded left hepatectomy (segments I,
II, III and IV), performed with temporary clamping of the
hepatic hilum. The gallbladder and the extrahepatic biliary tract
were also resected due to proximity of the lesion and as a
surgical tactics. The biliary tract was reconstructed with
hepaticojejunostomy using a jejunal Roux-en-Y loop and non-
absorbable suture (prolene 6.0). The surgical procedure was
carried out uneventfully, and the patient is clinically well ten
months later. The histological examination of the surgical
specimen confirmed the diagnosis of multifocal papillary
adenocarcinoma of the biliary tract, infiltrating adjacent
connective tissue. The surgical margins of the bile duct and liver
parenchyma showed no signs of malignancy.
DISCUSSION
Resection of biliary tract tumor remains a challenge for
surgeons and numerous studies recently published show that
there are few cases of cure(2). Cholangiocarcinoma presents
typically as a sclerosing adenocarcinoma that can extend from
the liver parenchyma to the distal bile ducts. Some signs suggest
poorer prognosis: obstructive jaundice, serum albumin levels <
35 g/L, need for extensive liver and/or vascular resections, and a
location proximal to the bile duct(3-4). Non-invasive diagnostic
methods (3D CT, MR cholangiography) enable precise tumor
staging in addition to correct selection of patients to whom
surgery is indicated(5). Some centers point out the importance of
gene p53 mutation in the pathogenesis of cholangiocarcinoma
and emphasize its identification in routine staging(2).
The general consensus has shown that surgery with complete
tumor resection and free surgical margins is the treatment with
the best prognosis and the only chance of cure(5); postoperative
chemotherapy or radiotherapy do not seem to change survival or
recurrence rates, even in cases with complete resection(6). On the
other hand, radical surgical treatment may be contraindicated in
some situations, such as presence of distant metastases, invasion
of the portal vein or adjacent vascular structures or need for
extensive liver resections(7). These situations occur in most cases
in which palliative measures should be performed, such as
endoscopic stenting in biliary tree, percutaneous transhepatic
biliary drainage and cholangio-enteric bypass; these procedures
aim at relieving jaundice and/or cholangitis, improving clinical
status and extending patient survival(2,6).
Survival rates have improved as surgical interventions have
progressively become more aggressive. However, surgeries with
extensive resections have increased hospital morbidity and
mortality rates(4). Due to its local invasive nature, most specialized
centers have performed partial hepatectomies in 50 to 100% of
the cases(5). A large series assessed in Italy showed the need for
caudate hepatectomy as a statistically significant factor for 5-year
survival rate (25% for patients submitted to caudate hepatectomy
and for those not submitted it was zero)(7). In several centers, the
5-year survival rate for patients submitted to curative surgery varied
from 7 to 33%(2,7-9).
Prognostic factors related to longer survival are associated with
free surgical margins, absence of nodal metastases, tumor histology,
absence of gene p53 mutation and no invasion of adjacent vascular
structures(1,2,10).
A recent study carried out in Japan using tumor necrosis factor
(TNF) receptors, showed its promising role as an antitumor agent
for treating human cholangiocarcinoma(11). Further clinical trials
are required to better establish the role of this agent.
In the case reported in this study, the only sign of poor
prognosis presented was its location close to the bile duct. During
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surgery, it was possible to resect the tumor with free and expanded
margins and to verify there no local lymph nodes involved.
Comparing the case with literature reports, the chances of a
favorable long-term outcome are promising.
CONCLUSION
Early diagnosis by non-invasive methods and expanded local
resection with free surgical margins associated with partial
hepatectomy yield the best chances of survival for patients with
cholangiocarcinoma. Further studies are required to better clarify
the pathogenesis of cholangiocarcinoma. So far, surgical treatment
seems to be the only alternative to effect cure.
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